BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MDC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution: Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized, Controlled Trial. Hepatology 1998;27:1578-83. [DOI: 10.1002/hep.510270617] [Cited by in Crossref: 376] [Cited by in F6Publishing: 358] [Article Influence: 19.8] [Reference Citation Analysis]
Number Citing Articles
1 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
2 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73. [PMID: 19003878 DOI: 10.1002/hep.22546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
3 Llovet JM, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology. 2004;230:300-31; author reply 300-301;. [PMID: 14695404 DOI: 10.1148/radiol.2301030753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
4 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
5 Zhang H, Zhou D, Ying M, Chen M, Chen P, Chen Z, Zhang F. Expression of Long Non-Coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) Exacerbates Hepatocellular Carcinoma Through Suppressing miR-195. Med Sci Monit 2016;22:4820-9. [PMID: 27932778 DOI: 10.12659/msm.898574] [Cited by in Crossref: 71] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
6 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-099-9711-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Brown DB, Nikolic B, Covey AM, Nutting CW, Saad WE, Salem R, Sofocleous CT, Sze DY; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2012;23:287-294. [PMID: 22284821 DOI: 10.1016/j.jvir.2011.11.029] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 12.0] [Reference Citation Analysis]
8 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget 2017;8:66699-708. [PMID: 29029548 DOI: 10.18632/oncotarget.19449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
10 Kaufmann S, Horger T, Oelker A, Beck S, Schulze M, Nikolaou K, Ketelsen D, Horger M. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation. Eur J Radiol 2015;84:2548-54. [PMID: 26428842 DOI: 10.1016/j.ejrad.2015.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
12 Maluccio MA, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, Dematteo R, Blumgart LH, Fong Y, Brown KT. Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2008;19:862-9. [DOI: 10.1016/j.jvir.2008.02.013] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 7.9] [Reference Citation Analysis]
13 Favoulet P, Cercueil JP, Faure P, Osmak L, Isambert N, Beltramo JL, Cognet F, Krause D, Bedenne L, Chauffert B. Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs. 2001;12:801-806. [PMID: 11707647 DOI: 10.1097/00001813-200111000-00003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
14 Fukumoto T, Tominaga M, Kido M, Takebe A, Tanaka M, Kuramitsu K, Matsumoto I, Ajiki T, Ku Y. Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol. 2014;21:971-978. [PMID: 24201744 DOI: 10.1245/s10434-013-3305-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
15 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S, Kita R, Kimura T. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2012; 18(12): 1379-1384 [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
16 Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan D, Vedantham S, Miller DL, Brountzos EN, Grassi CJ, Towbin RB. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006;17:225-32. [PMID: 16517768 DOI: 10.1097/01.RVI.0000195330.47954.48] [Cited by in Crossref: 80] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
17 Xu HX, Xie XY, Lu MD, Chen JW, Yin XY, Xu ZF, Liu GJ. Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. Clin Radiol. 2004;59:53-61. [PMID: 14697375 DOI: 10.1016/j.crad.2003.09.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 4.2] [Reference Citation Analysis]
18 Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223-S229. [PMID: 12354840 DOI: 10.1016/s1051-0443(07)61790-4] [Cited by in Crossref: 178] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
19 Lin HS, Wan RH, Gao LH, Li JF, Shan RF, Shi J. Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis. Hepatobiliary Pancreat Dis Int. 2015;14:236-245. [PMID: 26063023 DOI: 10.1016/s1499-3872(15)60373-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, Sata M. Interventional Radiology for Advanced Hepatocellular Carcinoma: Comparison of Hepatic Artery Infusion Chemotherapy and Transcatheter Arterial Lipiodol Chemoembolization. American Journal of Roentgenology 2003;181:1327-34. [DOI: 10.2214/ajr.181.5.1811327] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
21 Kneuertz PJ, Kao LS, Ko TC, Wray CJ. Regional disparities affect treatment and survival of patients with intrahepatic cholangiocarcinoma--a Texas Cancer Registry analysis. J Surg Oncol 2014;110:416-21. [PMID: 24889699 DOI: 10.1002/jso.23664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
22 Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9:534-540. [PMID: 19039270 DOI: 10.3348/kjr.2008.9.6.534] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
23 Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155-168. [PMID: 16377509 DOI: 10.1016/j.jamcollsurg.2005.06.263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
24 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40. [PMID: 21931992 DOI: 10.1007/s13277-011-0237-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
25 Miyamoto A, Umeshita K, Sakon M, Nagano H, Eguchi H, Kishimoto S, Dono K, Nakamori S, Gotoh M, Monden M. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of α-interferon and oral tegafur/uracil. Journal of Gastroenterology and Hepatology 2000;15:1447-51. [DOI: 10.1046/j.1440-1746.2000.02289.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
26 Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005;31:331-347. [PMID: 15837037 DOI: 10.1016/j.ejso.2004.10.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
27 Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, Sakai H, Mera K, Maru Y, Yoshino M. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol. 2003;26:159-164. [PMID: 12714888 DOI: 10.1097/00000421-200304000-00012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
28 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 16.9] [Reference Citation Analysis]
29 Megìas Vericat JE, Garcia Marcos R, Lopez Briz E, Gòmez Munoz F, Ramos Ruiz J, Martinez Rodrigo JJ, Poveda Andrés JL. Trans-arterial Chemoembolization with Doxorubicin-eluting Particles versus Conventional Trans-arterial Chemoembolization in Unresectable Hepatocellular Carcinoma: a Study of Effectiveness, Safety and Costs. Radiologia. 2015;57:496-504. [PMID: 25857250 DOI: 10.1016/j.rx.2015.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
30 Livraghi T, Lazzaroni S, Meloni F. Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound. 2001;13:159-166. [PMID: 11369527 DOI: 10.1016/s0929-8266(01)00128-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
31 Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. Radiology 2008;249:346-54. [PMID: 18796686 DOI: 10.1148/radiol.2483071902] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
32 Abou-Alfa GK. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning? Oncologist. 2009;14:92-94. [PMID: 19144679 DOI: 10.1634/theoncologist.2008-0294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
33 Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000;73:109-14. [PMID: 10694648 DOI: 10.1002/(sici)1096-9098(200002)73:2<109::aid-jso10>3.0.co;2-j] [Cited by in Crossref: 101] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
34 Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-melman M, Chapman WC, Crippin JS. Hepatic Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison of Survival Rates with Different Embolic Agents. Journal of Vascular and Interventional Radiology 2005;16:1661-6. [DOI: 10.1097/01.rvi.0000182160.26798.a2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
35 Brown DB, Fundakowski CE, Lisker-Melman M, Crippin JS, Pilgram TK, Chapman W, Darcy MD. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004;15:1209-1218. [PMID: 15525739 DOI: 10.1097/01.rvi.0000128123.04554.c1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
36 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
37 Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan DK, Vedantham S, Miller DL, Brountzos EN, Grassi CJ, Towbin RB; SIR Standards of Practice Committee, Angle JF, Balter S, Clark TW, Cole PE, Drescher P, Freeman NJ, Georgia JD, Haskal Z, Hovsepian DM, Kilnani NM, Kundu S, Malloy PC, Martin LG, McGraw JK, Meranze SG, Meyers PM, Millward SF, Murphy K, Neithamer CD Jr, Omary RA, Patel NH, Roberts AC, Schwartzberg MS, Siskin GP, Smouse HR, Swan TL, Thorpe PE, Vesely TM, Wagner LK, Wiechmann BN, Bakal CW, Lewis CA, Nemcek AA Jr, Rholl KS. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2009;20:S219-S226, S226.e1-S226.10. [PMID: 19560002 DOI: 10.1016/j.jvir.2009.04.033] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
38 Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology 2015;205:764-73. [DOI: 10.2214/ajr.15.14825] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
39 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 753] [Article Influence: 40.1] [Reference Citation Analysis]
40 Okada S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology. 1998;27:1743-1744. [PMID: 9620352 DOI: 10.1002/hep.510270639] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
41 Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37-49. [PMID: 21069333 DOI: 10.1007/s00270-010-0012-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 6.4] [Reference Citation Analysis]
42 Mabed M, Esmaeel M, El-khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. European Journal of Cancer Care 2009;18:492-9. [DOI: 10.1111/j.1365-2354.2008.00984.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
43 Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization: Drop-Out Rates for HCC. Liver Transpl 2004;10:449-55. [DOI: 10.1002/lt.20099] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 9.3] [Reference Citation Analysis]
44 Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440. [PMID: 10573522 DOI: 10.1002/hep.510300629] [Cited by in Crossref: 1259] [Cited by in F6Publishing: 1142] [Article Influence: 54.7] [Reference Citation Analysis]
45 Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4:39-50. [PMID: 26020028 DOI: 10.1159/000367727] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 11.7] [Reference Citation Analysis]
46 Saverio Ferrari F, Stella A, Pasquinucci P, Vigni F, Civeli L, Pieraccini M, Magnolfi F. Treatment of small hepatocellular carcinoma: a comparison of techniques and long-term results: . European Journal of Gastroenterology & Hepatology 2006;18:659-72. [DOI: 10.1097/00042737-200606000-00014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
47 Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet 2002;359:1734-9. [DOI: 10.1016/s0140-6736(02)08649-x] [Cited by in Crossref: 2274] [Cited by in F6Publishing: 844] [Article Influence: 113.7] [Reference Citation Analysis]
48 Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer. 2012;1:201-215. [PMID: 24159585 DOI: 10.1159/000343835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
49 Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatol Int. 2017;11:292-299. [PMID: 28324324 DOI: 10.1007/s12072-017-9792-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1290] [Cited by in F6Publishing: 1210] [Article Influence: 322.5] [Reference Citation Analysis]
51 Sun X, Jiang H, Jiang X, Tan H, Meng Q, Sun B, Xu R, Krissansen GW. Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther. 2009;20:314-324. [PMID: 19327024 DOI: 10.1089/hum.2008.164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
52 Bruix J, Llovet JM. Locoregional treatments for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:611-622. [PMID: 10654923 DOI: 10.1053/bega.1999.0051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
53 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 320] [Article Influence: 26.9] [Reference Citation Analysis]
54 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
55 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
56 Yip D, Findlay M, Boyer M, Tattersall MH. Hepatocellular carcinoma in central Sydney: a 10 year review of patients seen in a medical oncology department. World J Gastroenterol 1999; 5(6): 483-487 [PMID: 11819496 DOI: 10.3748/wjg.v5.i6.483] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
57 Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN. Advances in the surgical management of liver malignancies. Cancer J 2004;10:74-87. [PMID: 15130267 DOI: 10.1097/00130404-200403000-00003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
58 Iwamoto S, Sanefuji H, Okuda K. Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma. Cancer 2003;97:1051-6. [DOI: 10.1002/cncr.11106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
59 Pillai AA, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis 2020;24:681-700. [PMID: 33012453 DOI: 10.1016/j.cld.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T; Japan Interventional Radiology in Oncology Study Group (JIVROSG); Korea Interventional Radiology in Oncology Study Group (KIVROSG). Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol. 2013;24:490-500. [PMID: 23466316 DOI: 10.1016/j.jvir.2013.01.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
61 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
62 Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2012;35:1094-1101. [PMID: 22069121 DOI: 10.1007/s00270-011-0292-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
63 Kalra N, Gupta P, Chawla Y, Khandelwal N. Locoregional treatment for hepatocellular carcinoma: The best is yet to come. World J Radiol 2015; 7(10): 306-318 [PMID: 26516427 DOI: 10.4329/wjr.v7.i10.306] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
64 Jin C, Zhu H, Wang Z, Wu F, Chen W, Li K, Su H, Zhou K, Gong W. High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: long-term follow-up and clinical analysis. Eur J Radiol. 2011;80:662-669. [PMID: 20864286 DOI: 10.1016/j.ejrad.2010.08.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
65 Trinchet JC, Ganne-Carrie N, Beaugrand M. Review article: intra-arterial treatments in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17 Suppl 2:111-118. [PMID: 12786622 DOI: 10.1046/j.1365-2036.17.s2.19.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
66 Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16:195-203. [PMID: 15713920 DOI: 10.1097/01.rvi.0000142602.79459.90] [Cited by in Crossref: 87] [Cited by in F6Publishing: 19] [Article Influence: 5.1] [Reference Citation Analysis]
67 Nagae G, Ido K, Isoda N, Sato S, Kita H, Sugano K. LAPAROSCOPIC ABLATION THERAPY FOR HEPATOCELLULAR CARCINOMA. Dig Endosc 2005;17:1-8. [DOI: 10.1111/j.1443-1661.2005.00471.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Zou Y, Guo CG, Yang ZG, Sun JH, Zhang MM, Fu CY. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery. Drug Des Devel Ther 2016;10:1243-55. [PMID: 27069355 DOI: 10.2147/DDDT.S94122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
69 Meng MB, Cui YL, Guan YS, Ying Z, Zheng MH, Yuan CK, Zhang RM. Traditional Chinese medicine plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. J Altern Complement Med 2008;14:1027-42. [PMID: 18990050 DOI: 10.1089/acm.2008.0060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
70 Ruff P. Therapeutic Options in Hepatocellular Carcinoma: . American Journal of Cancer 2004;3:119-31. [DOI: 10.2165/00024669-200403020-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Kim DY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Shin SW, Choo SW, Do YS, Rhee JC. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006; 12(43): 6992-6997 [PMID: 17109521 DOI: 10.3748/wjg.v12.i43.6992] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
72 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
74 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
75 Sanda H, Kawai N, Sato M, Tanaka F, Ikoma A, Nakai M, Minamiguchi H, Sonomura T, Matsuzaki I, Warigaya K, Murata S. Synthesis of 24-h soluble gelatin sponge particles and their effect on liver necrosis following hepatic artery embolization: Results of in vitro and in vivo studies. Hepatol Res 2016;46:335-42. [PMID: 26037384 DOI: 10.1111/hepr.12539] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
77 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
78 Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 1646. [PMID: 17912593 DOI: 10.1007/s11605-007-0315-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
79 Hourmand-Ollivier I, Chiche L. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. J Chir (Paris) 2004;141:71-83. [PMID: 15133430 DOI: 10.1016/s0021-7697(04)95574-3] [Reference Citation Analysis]
80 Caturelli E, Siena DA, Villani MR, Schiavone G, Nardella M, Balzana S, Florio F. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology. 2000;215:123-128. [PMID: 10751477 DOI: 10.1148/radiology.215.1.r00ap21123] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 3.1] [Reference Citation Analysis]
81 Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, Luketic V, Shiffman ML, Sterling R, Posner MP, Fisher RA. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc 2007;39:153-9. [PMID: 17275495 DOI: 10.1016/j.transproceed.2006.10.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
82 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Mizuki A, Tatemichi M, Tsukada N, Nagamatsu R, Kawaguchi M, Itoshima T, Maruyama S, Satou A, Imari Y, Kawatoko T. Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: A multicenter randomized control study. Oncol Lett. 2010;1:855-859. [PMID: 22966394 DOI: 10.3892/ol_00000151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
84 Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JA, Schoenfeld PS. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569-577. [PMID: 20978844 DOI: 10.1007/s10620-010-1453-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
85 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
86 Crosbie OM, Alexander GJ. Liver transplantation for hepatitis C virus related cirrhosis. Best Practice & Research Clinical Gastroenterology 2000;14:307-25. [DOI: 10.1053/bega.1999.0078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
87 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
88 Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int. 2004;24:419-424. [PMID: 15482337 DOI: 10.1111/j.1478-3231.2004.0941.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
89 Yuan Z, Ye XD, Dong S, Xu LC, Xu XY, Liu SY, Xiao XS. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol. 2010;75:e9-14. [PMID: 19540083 DOI: 10.1016/j.ejrad.2009.05.040] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
90 Satake M, Uchida H, Arai Y, Anai H, Sakaguchi H, Nagata T, Yamane T, Kichikawa K, Osaki Y, Okazaki M, Higashihara H, Nakamura H, Osuga K, Nakao N, Hirota S. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 2008;31:756-61. [PMID: 18389187 DOI: 10.1007/s00270-007-9255-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
91 Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24(2): 161-169 [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
92 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202. [PMID: 21615953 DOI: 10.1186/1471-2407-11-202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
93 Solorio L, Patel RB, Wu H, Krupka T, Exner AA. Advances in image-guided intratumoral drug delivery techniques. Ther Deliv 2010;1:307-22. [PMID: 22816134 DOI: 10.4155/tde.10.20] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
94 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
95 Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52 Suppl 3:iii1-iii8. [PMID: 12692148 DOI: 10.1136/gut.52.suppl_3.iii1] [Cited by in Crossref: 132] [Cited by in F6Publishing: 176] [Article Influence: 6.9] [Reference Citation Analysis]
96 Liang B, Zheng C, Feng G, Wu H, Wang Y, Zhao H, Li X, Qian J, Liang H. Experimental evaluation of inhibitory effect of 10-hydroxycamptothecin on hypoxia-inducible factor-1α expression and angiogenesis in liver tumors after transcatheter arterial embolization. J Vasc Interv Radiol. 2010;21:1565-1572. [PMID: 20810290 DOI: 10.1016/j.jvir.2010.05.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
97 Nicolini A, Crespi S, Martinetti L. Drug delivery embolization systems: a physician's perspective. Expert Opin Drug Deliv 2011;8:1071-84. [PMID: 21692688 DOI: 10.1517/17425247.2011.590472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
98 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
99 Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 2001;32:383-389. [PMID: 11319307 DOI: 10.1097/00004836-200105000-00005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 3.9] [Reference Citation Analysis]
100 Zhao R, Zhou J, Wei Y, Liu F, Chen K, Li Q, Li B. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2017;16:493-8. [DOI: 10.1016/s1499-3872(17)60009-2] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
101 Maluf D, Fisher RA, Maroney T, Cotterell A, Fulcher A, Tisnado J, Contos M, Luketic V, Stravitz R, Shiffman M. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant. 2003;3:312-317. [PMID: 12614287 DOI: 10.1034/j.1600-6143.2003.00041.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
102 Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, Chung JW, Park JH, Kim CY. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol. 2002;20:4459-4465. [PMID: 12431969 DOI: 10.1200/jco.2002.02.013] [Cited by in Crossref: 86] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
103 Chiadmi F, Daroso J, Schlatter J, Cisternino S, Ratiney R, Fontan JE. Stability of doxorubicin combined with RadioselectanR, a contrast agent, for chemoembolization. J Clin Pharm Ther 2005;30:255-8. [DOI: 10.1111/j.1365-2710.2005.00654.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64:106-116. [PMID: 26765068 DOI: 10.1002/hep.28453] [Cited by in Crossref: 226] [Cited by in F6Publishing: 208] [Article Influence: 37.7] [Reference Citation Analysis]
105 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 11.7] [Reference Citation Analysis]
106 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25. [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3] [Cited by in Crossref: 552] [Cited by in F6Publishing: 493] [Article Influence: 36.8] [Reference Citation Analysis]
107 Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, Owen R. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012;38:54-62. [PMID: 21726960 DOI: 10.1016/j.ctrv.2011.05.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
108 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
109 Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V, Tindilière F, Laurent A, Bellin MF, Bismuth H. Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg. 2003;238:241-248. [PMID: 12894018 DOI: 10.1097/01.sla.0000080959.95226.be] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
110 Pacella CM, Bizzarri G, Cecconi P, Caspani B, Magnolfi F, Bianchini A, Anelli V, Pacella S, Rossi Z. Hepatocellular Carcinoma: Long-term Results of Combined Treatment with Laser Thermal Ablation and Transcatheter Arterial Chemoembolization. Radiology 2001;219:669-78. [DOI: 10.1148/radiology.219.3.r01ma02669] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
111 Saccheri S, Lovaria A, Sangiovanni A, Nicolini A, De Fazio C, Ronchi G, Fasani P, Del Ninno E, Colombo M. Segmental Transcatheter Arterial Chemoembolization Treatment in Patients with Cirrhosis and Inoperable Hepatocellular Carcinomas. Journal of Vascular and Interventional Radiology 2002;13:995-9. [DOI: 10.1016/s1051-0443(07)61863-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
112 Riaz A, Lewandowski RJ, Salem R. Locoregional Therapies for Primary and Secondary Hepatic Malignancies. In: Bentrem D, Benson AB, editors. Gastrointestinal Malignancies. Cham: Springer International Publishing; 2016. pp. 233-56. [DOI: 10.1007/978-3-319-34244-3_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
113 Tang ZY. Hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15 Suppl:G1-G7. [PMID: 11100985 DOI: 10.1046/j.1440-1746.2000.02257.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
114 Ramsey DE, Geschwind JH. New interventions for liver tumors. Seminars in Roentgenology 2002;37:303-11. [DOI: 10.1016/s0037-198x(02)80007-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Myers RP. Meta-analysis of transarterial embolization in patients with unresectable hepatocellular carcinoma. Radiology 2003;227:611-2; author reply 612-3. [PMID: 12732709 DOI: 10.1148/radiol.2272021187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
116 Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552-559. [PMID: 19957182 DOI: 10.1007/s00270-009-9752-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 5.2] [Reference Citation Analysis]
117 Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrocholoride emulsion. J Vasc Intervent Radiol. 2001;12:847-854. [PMID: 11435541 DOI: 10.1016/s1051-0443(07)61510-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
118 Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015;15:392. [PMID: 25957784 DOI: 10.1186/s12885-015-1373-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
119 Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51:1030-1036. [PMID: 19864035 DOI: 10.1016/j.jhep.2009.09.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
120 Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl 2000;6:s11-5. [DOI: 10.1053/jlts.2000.18684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
121 Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171. [PMID: 11981766 DOI: 10.1053/jhep.2002.33156] [Cited by in Crossref: 1745] [Cited by in F6Publishing: 1579] [Article Influence: 87.3] [Reference Citation Analysis]
122 Bower M, Metzger T, Robbins K, Tomalty D, Válek V, Boudný J, Andrasina T, Tatum C, Martin RC. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB s. 2010;12:31-36. [PMID: 20495642 DOI: 10.1111/j.1477-2574.2009.00117.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
123 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
124 Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2017; 9(18): 808-814 [PMID: 28706579 DOI: 10.4254/wjh.v9.i18.808] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
125 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
126 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-442. [PMID: 12540794 DOI: 10.1053/jhep.2003.50047] [Cited by in Crossref: 2017] [Cited by in F6Publishing: 1839] [Article Influence: 106.2] [Reference Citation Analysis]
127 Hiraoka A, Kumagi T, Hirooka M, Uehara T, Kurose K, Iuchi H, Hiasa Y, Matsuura B, Michitaka K, Kumano S, Tanaka H, Yamashita Y, Horiike N, Mochizuki T, Onji M. Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol 2006; 12(13): 2075-2079 [PMID: 16610060 DOI: 10.3748/wjg.v12.i13.2075] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
128 Li CX, Yu B, Shi L, Geng W, Lin QB, Ling CC, Yang M, Ng KT, Huang JD, Man K. 'Obligate' anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice. Oncol Lett 2017;13:177-83. [PMID: 28123538 DOI: 10.3892/ol.2016.5453] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
129 Bai MY, Tang SL, Chuang MH, Wang TY, Hong PD. Evaluation of Chitosan Derivative Microparticles Encapsulating Superparamagnetic Iron Oxide and Doxorubicin as a pH-Sensitive Delivery Carrier in Hepatic Carcinoma Treatment: An in vitro Comparison Study. Front Pharmacol 2018;9:1025. [PMID: 30298001 DOI: 10.3389/fphar.2018.01025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
130 Siddique I, El-Naga HA, Memon A, Thalib L, Hasan F, Al-Nakib B. CLIP score as a prognostic indicator for hepatocellular carcinoma: experience with patients in the Middle East. Eur J Gastroenterol Hepatol. 2004;16:675-680. [PMID: 15201581 DOI: 10.1097/01.meg.0000108338.41221.ec] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
131 Nakano H, Yoshida K, Takeuchi S, Kumada K, Yamaguchi M, Jaeck D. Liver scintigraphy is useful for selecting candidates for preoperative transarterial chemoembolization among patients with hepatocellular carcinoma and chronic liver disease. Am J Surg. 1999;178:385-389. [PMID: 10612533 DOI: 10.1016/s0002-9610(99)00195-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
132 Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol. 2012;42:247-255. [PMID: 22407946 DOI: 10.1093/jjco/hys020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
133 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
134 Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatology Research 2007;37:S230-7. [DOI: 10.1111/j.1872-034x.2007.00190.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
135 Sithinamsuwan P, Piratvisuth T, Tanomkiat W, Apakupakul N, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol 2000; 6(3): 339-343 [PMID: 11819593 DOI: 10.3748/wjg.v6.i3.339] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
136 Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67. [PMID: 9862851 DOI: 10.1002/hep.510290145] [Cited by in Crossref: 765] [Cited by in F6Publishing: 742] [Article Influence: 33.3] [Reference Citation Analysis]
137 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1064] [Article Influence: 155.6] [Reference Citation Analysis]
138 Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31:54-58. [PMID: 10613728 DOI: 10.1002/hep.510310111] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 8.1] [Reference Citation Analysis]
139 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7] [Cited by in Crossref: 948] [Cited by in F6Publishing: 822] [Article Influence: 72.9] [Reference Citation Analysis]
140 Colombo M. Treatment of hepatocellular carcinoma. Antiviral Res. 2001;52:209-215. [PMID: 11672831 DOI: 10.1016/s0166-3542(01)00186-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
141 Cheng Z, He L, Guo Y, Song Y, Song S, Zhang L. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World J Surg Oncol 2020;18:243. [PMID: 32917226 DOI: 10.1186/s12957-020-02017-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86. [PMID: 11923602 DOI: 10.1097/00000658-200204000-00004] [Cited by in Crossref: 300] [Cited by in F6Publishing: 283] [Article Influence: 15.0] [Reference Citation Analysis]
143 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
144 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 2015; 7(8): 1020-1029 [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 11.6] [Reference Citation Analysis]
145 Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 2007;109:1384-90. [DOI: 10.1002/cncr.22532] [Cited by in Crossref: 128] [Cited by in F6Publishing: 120] [Article Influence: 8.5] [Reference Citation Analysis]
146 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
147 Hickey RM, Lewandowski RJ, Salem R. Rationale of transcatheter intra-arterial therapies of hepatic cancers. Hepat Oncol 2014;1:285-91. [PMID: 30190963 DOI: 10.2217/hep.14.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
148 Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007;10:2-11. [PMID: 17980314 DOI: 10.1053/j.tvir.2007.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
149 Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 2004;40:1465-73. [PMID: 15565604 DOI: 10.1002/hep.20528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
150 Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-1283. [PMID: 20112254 DOI: 10.1002/hep.23485] [Cited by in Crossref: 249] [Cited by in F6Publishing: 230] [Article Influence: 20.8] [Reference Citation Analysis]
151 Lanza E, Muglia R, Bolengo I, Poretti D, D'Antuono F, Ceriani R, Torzilli G, Pedicini V. Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization. PLoS One 2020;15:e0227711. [PMID: 31935255 DOI: 10.1371/journal.pone.0227711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Guan YS, He Q, Wang MQ. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012;2012:480650. [PMID: 22966466 DOI: 10.5402/2012/480650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
153 Delhaye C, Hendlisz A, Vouche M. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. Curr Opin Oncol 2019;31:339-45. [PMID: 30896451 DOI: 10.1097/CCO.0000000000000539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-9. [PMID: 22846867 DOI: 10.1053/j.seminoncol.2012.05.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
155 Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165-1174. [PMID: 12474157 DOI: 10.1053/jlts.2002.36394] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 6.2] [Reference Citation Analysis]
156 Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:49-56. [PMID: 17296704 DOI: 10.1016/j.jvir.2006.10.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 6.3] [Reference Citation Analysis]
157 Orlando A, D'antoni A, Cammà C, Albanese M, Livraghi T, Torzill G, Virdone R, Sciarrino E, Simonetti RG, Maringhini A, Pagliaro L, Cottone M. Treatment of Small Hepatocellular Carcinoma With Percutaneous Ethanol Injection: A Validated Prognostic Model. American Journal of Gastroenterology 2000;95:2921-7. [DOI: 10.1111/j.1572-0241.2000.03205.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
158 Takaki S, Sakaguchi H, Anai H, Tanaka T, Yamamoto K, Morimoto K, Nishiofuku H, Inoue M, Sueyoshi S, Nagata T. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35:544-554. [PMID: 21739345 DOI: 10.1007/s00270-011-0224-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
159 Goode JA, Matson MB. Embolisation of cancer: what is the evidence? Cancer Imaging 2004;4:133-41. [PMID: 18250022 DOI: 10.1102/1470-7330.2004.0021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
160 Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590-599. [PMID: 22438359 DOI: 10.1148/radiol.12111550] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 12.6] [Reference Citation Analysis]
161 Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, Suou T, Kawasaki H. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: A randomized control study. Cancer 2001;92:1516-24. [DOI: 10.1002/1097-0142(20010915)92:6<1516::aid-cncr1477>3.0.co;2-i] [Cited by in Crossref: 104] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
162 Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466-473. [PMID: 19188315 DOI: 10.1148/radiol.2502072222] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 11.1] [Reference Citation Analysis]
163 Shelgikar CS, Loehle J, Scoggins CR, Mcmasters KM, Martin RC. Empiric Antibiotics for Transarterial Embolization in Hepatocellular Carcinoma: Indicated? Journal of Surgical Research 2009;151:121-4. [DOI: 10.1016/j.jss.2008.02.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
164 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313-320. [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
165 Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 2002;35:S115-29. [PMID: 12394215 DOI: 10.1097/00004836-200211002-00008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
166 Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25:1089-1104. [PMID: 18972075 DOI: 10.1007/s12325-008-0113-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
167 Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, Tateishi R, Imamura M, Hamamura K, Teratani T. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int. 2004;24:625-629. [PMID: 15566514 DOI: 10.1111/j.1478-3231.2004.0963.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
168 Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am. 2003;12:105-126. [PMID: 12735133 DOI: 10.1016/s1055-3207(02)00089-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
169 Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47-54. [PMID: 12091661 DOI: 10.1148/radiol.2241011262] [Cited by in Crossref: 583] [Cited by in F6Publishing: 513] [Article Influence: 29.2] [Reference Citation Analysis]
170 Varela M, Sala M, Llovet JM, Bruix J. Natural history and prognostic prediction of patients with hepatocellular carcinoma: REVIEW: NATURAL HISTORY AND PROGNOSTIC PREDICTION. Alimentary Pharmacology & Therapeutics 2003;17:98-102. [DOI: 10.1046/j.1365-2036.17.s2.11.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
171 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-3491471-2407-8-349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Robinson MK, Weiner LM, Adams GP. Improving mono-clonal antibodies for cancer therapy. Drug Development Res. 2004;61:172-187. [PMID: 11819809 DOI: 10.1002/ddr.10345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
173 Huang L, Jiang X, Wang Z, Zhong X, Tai S, Cui Y. Small nucleolar RNA host gene 1: A new biomarker and therapeutic target for cancers. Pathol Res Pract 2018;214:1247-52. [PMID: 30107989 DOI: 10.1016/j.prp.2018.07.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
174 Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639. [PMID: 16371529 DOI: 10.1097/01.rvi.0000184594.01661.81] [Cited by in Crossref: 294] [Cited by in F6Publishing: 69] [Article Influence: 18.4] [Reference Citation Analysis]
175 Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;3:CD006745. [PMID: 19588401 DOI: 10.1002/14651858.cd006745.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
176 Baba Y, Hayashi S, Ueno K, Nakajo M, Ueno S, Kubo F, Baba Y, Hamanoue M, Hasegawa S, Tsubouchi H, Komorizono Y. Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncol Lett 2010;1:905-11. [PMID: 22966404 DOI: 10.3892/ol_00000161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY, Lee SD. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 2006;23:129-35. [PMID: 16393290 DOI: 10.1111/j.1365-2036.2006.02704.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
178 Deltenre P, Valla DC. Ischemic cholangiopathy. J Hepatol. 2006;44:806-817. [PMID: 16488506 DOI: 10.1016/j.jhep.2006.01.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
179 Tang ZY. Hepatocellular Carcinoma-Cause, Treatment and Metastasis. World J Gastroenterol 2001; 7(4): 445-454 [PMID: 11819809 DOI: 10.3748/wjg.v7.i4.445] [Cited by in CrossRef: 277] [Cited by in F6Publishing: 269] [Article Influence: 13.2] [Reference Citation Analysis]
180 Piscaglia F, Terzi E, Cucchetti A, Trimarchi C, Granito A, Leoni S, Marinelli S, Pini P, Bolondi L. Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease 2013;45:852-8. [DOI: 10.1016/j.dld.2013.03.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
181 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
182 Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer 2003;39:2150-64. [PMID: 14522372 DOI: 10.1016/s0959-8049(03)00553-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
183 Cheng X, Sun P, Hu Q, Song Z, Xiong J, Zheng Q. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. J Cancer Res Clin Oncol 2014;140:1159-70. [DOI: 10.1007/s00432-014-1677-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
184 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
185 Lake-Bakaar G, Ahmed M, Evenson A, Bonder A, Faintuch S, Sundaram V. Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer 2014;3:428-38. [PMID: 26280004 DOI: 10.1159/000343871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
186 Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options in Oncol 2001;2:473-83. [DOI: 10.1007/s11864-001-0069-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
187 Shi Y, Zhai B. A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:90-102. [PMID: 27904861 DOI: 10.1159/000445888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
188 Reichman TW, Bahramipour P, Barone A, Koneru B, Fisher A, Contractor D, Wilson D, Dela Torre A, Cho KC, Samanta A. Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg. 2005;9:638-645. [PMID: 15862257 DOI: 10.1016/j.gassur.2004.11.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
189 Befeler AS. Chemoembolization and bland embolization: a critical appraisal. Clin Liver Dis 2005;9:287-300, vii. [PMID: 15831274 DOI: 10.1016/j.cld.2004.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
190 Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010;29:164. [PMID: 21159184 DOI: 10.1186/1756-9966-29-164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
191 Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, Meng ZQ, Feng Y. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003; 9(8): 1697-1701 [PMID: 12918103 DOI: 10.3748/wjg.v9.i8.1697] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
192 Jakobs TF, Hoffmann R, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur Radiol 2007;17:1320-30. [DOI: 10.1007/s00330-006-0508-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
193 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
194 Llovet JM, Vilana R, Bianchi L, Brú C. [Radiofrequency in the treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2001;24:303-11. [PMID: 11459568 DOI: 10.1016/s0210-5705(01)70180-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742. [PMID: 19805671 DOI: 10.1200/jco.2009.23.1282] [Cited by in Crossref: 155] [Cited by in F6Publishing: 73] [Article Influence: 11.9] [Reference Citation Analysis]
196 Zalinski S, Scatton O, Randone B, Vignaux O, Dousset B. Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. World J Gastroenterol 2008; 14(44): 6869-6872 [PMID: 19058317 DOI: 10.3748/wjg.14.6869] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
197 Roche A. Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. In: Bartolozzi C, Lencioni R, editors. Liver Malignancies. Berlin: Springer Berlin Heidelberg; 1999. pp. 255-74. [DOI: 10.1007/978-3-642-58641-5_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
198 Morimoto M, Kobayashi S, Moriya S, Ueno M, Tezuka S, Irie K, Goda Y, Ohkawa S. Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization. Abdom Radiol 2017;42:612-9. [DOI: 10.1007/s00261-016-0900-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
199 Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002;35:S138-S142. [PMID: 12394217 DOI: 10.1097/00004836-200211002-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
200 Cascinu S, Labianca R, Daniele B, Beretta G, Salvagni S. Survival and quality of life in gastrointestinal tumors: two different end points? Ann Oncol 2001;12 Suppl 3:S31-6. [PMID: 11804382 DOI: 10.1093/annonc/12.suppl_3.s31] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
201 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
202 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
203 Kwok PC, Lam TW, Chan SC, Chung CP, Wong WK, Chan MK, Lo HY, Lam WM. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol. 2000;32:955-964. [PMID: 10898316 DOI: 10.1016/s0168-8278(00)80100-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
204 Mazzanti R, Giallombardo AL, Mini E, Nobili S, Neri B, Arena U, Pantaleo P, Fabbroni V, Ghilardi M, Gattai R. Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. Dig Liver Dis. 2004;36:278-285. [PMID: 15115341 DOI: 10.1016/j.dld.2003.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
205 Talenfeld AD, Sista AK, Madoff DC. Transarterial therapies for primary liver tumors. Surg Oncol Clin N Am. 2014;23:323-351. [PMID: 24560113 DOI: 10.1016/j.soc.2013.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
206 Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, McMasters KM, Martin RC. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg. 2009;208:375-382. [PMID: 19317999 DOI: 10.1016/j.jamcollsurg.2008.12.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
207 Ahmad J, Rhee J, Carr BI. The Effects of Hepatic Artery Chemotherapy on Viral Hepatitis in Patients With Hepatocellular Carcinoma. Dig Dis Sci 2005;50:331-5. [DOI: 10.1007/s10620-005-1606-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
208 Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol. 2011;41:770-775. [PMID: 21459893 DOI: 10.1093/jjco/hyr037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
209 Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol. 2006;17:1335-1343. [PMID: 16923981 DOI: 10.1097/01.rvi.0000228416.21560.7f] [Cited by in Crossref: 140] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
210 Xu L, Wang S, Wang S, Wang Y, Li W, Lin G, Yuan Z. Baseline apparent diffusion coefficients: Validation study of new predictor of survival in patients with unresectable hepatocellular carcinoma following chemoembolization. J Xray Sci Technol 2021;29:507-16. [PMID: 33814481 DOI: 10.3233/XST-200827] [Reference Citation Analysis]
211 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
212 Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005;25:1189-1196. [PMID: 16343071 DOI: 10.1111/j.1478-3231.2005.01170.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 5.4] [Reference Citation Analysis]
213 Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J; for the Barcelona Cly'nic Liver Cancer (BCLC) Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60. [DOI: 10.1002/hep.20465] [Cited by in Crossref: 330] [Cited by in F6Publishing: 289] [Article Influence: 18.3] [Reference Citation Analysis]
214 Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
215 Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, Delis S, Gouliamos A, Kelekis D. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269-280. [PMID: 17999110 DOI: 10.1007/s00270-007-9226-z] [Cited by in Crossref: 162] [Cited by in F6Publishing: 151] [Article Influence: 10.8] [Reference Citation Analysis]
216 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
217 Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;73:1155-1163. [PMID: 18760547 DOI: 10.1016/j.ijrobp.2008.06.1486] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
218 Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, Peachey M. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001;37:1352-8. [PMID: 11435064 DOI: 10.1016/s0959-8049(01)00100-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
219 Sugino Y, Yamakado K, Yamanaka T, Fujimori M, Nakatsuka A, Takaki H, Takei Y, Sakuma H, Isaji S. Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma. Jpn J Radiol 2017;35:254-61. [PMID: 28357723 DOI: 10.1007/s11604-017-0628-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
220 Callado França A, Lescano Lescano M, Candolo Martinelli A. Tratamiento combinado coadyuvante para el carcinoma hepatocelular previo al trasplante hepático. Gastroenterología y Hepatología 2002;25:153-5. [DOI: 10.1016/s0210-5705(02)79009-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
221 Zhang L, Zhu H, Jin C, Zhou K, Li K, Su H, Chen W, Bai J, Wang Z. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol. 2009;19:437-445. [PMID: 18795303 DOI: 10.1007/s00330-008-1137-0] [Cited by in Crossref: 138] [Cited by in F6Publishing: 114] [Article Influence: 9.9] [Reference Citation Analysis]
222 Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469. [PMID: 16890600 DOI: 10.1053/j.gastro.2006.05.021] [Cited by in Crossref: 524] [Cited by in F6Publishing: 494] [Article Influence: 32.8] [Reference Citation Analysis]
223 Li M, Yang Y, Kuang Y, Gan X, Zeng W, Liu Y, Guan H. miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2. Exp Ther Med. 2017;13:2279-2285. [PMID: 28565839 DOI: 10.3892/etm.2017.4244] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
224 Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000;14:991-1008. [PMID: 11139351 DOI: 10.1053/bega.2000.0143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
225 Sutphin PD, Lamus D, Kalva SP, Li J, Corbin IR. Interventional Radiologic Therapies for Hepatocellular Carcinoma: From Where We Began to Where We Are Going. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 169-94. [DOI: 10.1007/978-3-030-21540-8_9] [Reference Citation Analysis]
226 Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2006;17:217-223. [PMID: 16517767 DOI: 10.1097/01.rvi.0000196277.76812.a3] [Cited by in Crossref: 73] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
227 Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol. 2011;22:917-923. [PMID: 21571545 DOI: 10.1016/j.jvir.2011.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 5.5] [Reference Citation Analysis]
228 Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, Terai S, Sakaida I. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol 2011;46:359-66. [DOI: 10.1007/s00535-010-0306-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
229 Steinmüller T, Jonas S, Neuhaus P. Review article: liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17 Suppl 2:138-144. [PMID: 12786625 DOI: 10.1046/j.1365-2036.17.s2.2.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
230 Knab LM, Salem R, Mahvi DM. Minimally invasive therapies for hepatic malignancy. Curr Probl Surg 2013;50:146-79. [PMID: 23507316 DOI: 10.1067/j.cpsurg.2013.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
231 Achenbach T, Seifert JK, Pitton MB, Schunk K, Junginger T. Chemoembolization for primary liver cancer. Eur J Surg Oncol. 2002;28:37-41. [PMID: 11869011 DOI: 10.1053/ejso.2001.1181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
232 Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, Wu JY, Dai Y, Yan K. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res 2009;39:231-40. [PMID: 19054154 DOI: 10.1111/j.1872-034X.2008.00451.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
233 Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S211-S221. [PMID: 12354839 DOI: 10.1016/s1051-0443(07)61789-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
234 Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol. 2009;2:45-57. [PMID: 21180533 DOI: 10.1177/1756283X08100328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
235 Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978-986. [PMID: 17350947 DOI: 10.1200/jco.2006.09.8657] [Cited by in Crossref: 129] [Cited by in F6Publishing: 55] [Article Influence: 8.6] [Reference Citation Analysis]
236 Huang NC, Kuo YC, Chiang JC, Hung SY, Wang HM, Hung YM, Chang YT, Wann SR, Chang HT, Wang JS, Ho SY, Guo HR. Hepatic angiosarcoma may have fair survival nowadays. Medicine (Baltimore). 2015;94:e816. [PMID: 25984668 DOI: 10.1097/md.0000000000000816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
237 Sutcliffe R, Maguire D, Portmann B, Rela M, Heaton N. Selection of patients with hepatocellular carcinoma for liver transplantation. British Journal of Surgery 2006;93:11-8. [DOI: 10.1002/bjs.5198] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
238 Tsai Y, Hsu C, Huang Y, Su C, Lin H, Lee R, Chiang J, Huo T, Lee S. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975-84. [DOI: 10.1007/s12072-011-9276-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
239 Han K, Lee JT, Seong J. Treatment of non-resectable hepatocellular carcinoma: Non-resectable HCC. Journal of Gastroenterology and Hepatology 2002;17:S424-7. [DOI: 10.1046/j.1440-1746.17.s3.39.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
240 Inoue K, Nakamura T, Kinoshita T, Konishi M, Nakagohri T, Oda T, Takahashi S, Gotohda N, Hayashi T, Nawano S. Volume reduction surgery for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:362-366. [PMID: 15034789 DOI: 10.1007/s00432-004-0566-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
241 Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol. 2008;31:1133-1140. [PMID: 18584240 DOI: 10.1007/s00270-008-9379-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
242 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216-224. [PMID: 22142656 DOI: 10.1016/j.critrevonc.2011.10.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
243 Beaugrand M, Trinchet JC. [Non-surgical treatment of hepatocellular carcinoma. An overview]. Cancer Radiother 2005;9:464-9. [PMID: 16236541 DOI: 10.1016/j.canrad.2005.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
244 Zhou Y, Zhang X, Wu L, Ye F, Su X, Shi L, Li B. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol. 2013;13:51. [PMID: 23509884 DOI: 10.1186/1471-230x-13-51] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
245 Hoshida Y, Ikeda K, Kobayashi M, Suzuki Y, Tsubota A, Saitoh S, Arase Y, Kobayashi M, Murashima N, Chayama K, Kumada H. Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. J Hepatol. 1999;31:860-866. [PMID: 10580583 DOI: 10.1016/s0168-8278(99)80287-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
246 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
247 Staunton M, Dodd JD, McCormick PA, Malone DE. Finding evidence-based answers to practical questions in radiology: which patients with inoperable hepatocellular carcinoma will survive longer after transarterial chemoembolization? Radiology 2005;237:404-13. [PMID: 16244249 DOI: 10.1148/radiol.2372040058] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
248 Gianni S, Cecchetto A, Altavilla G, Ragazzi R, Bertazzo M, De Giorgio M, Baldan A, Fagiuoli S, Farinati F. Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma. J. Intern Med. 2005;257:367-373. [PMID: 15788007 DOI: 10.1111/j.1365-2796.2005.01460.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
249 Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88. [DOI: 10.1053/j.gastro.2004.09.032] [Cited by in Crossref: 369] [Cited by in F6Publishing: 337] [Article Influence: 20.5] [Reference Citation Analysis]
250 Toyoda H, Kumada T, Sone Y. Impact of a unified CT angiography system on outcome of patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2009;192:766-774. [PMID: 19234276 DOI: 10.2214/ajr.08.1368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
251 Suarez Y, França AC, Llovet JM, Fuster J, Bruix J. THE CURRENT STATUS OF LIVER TRANSPLANTATION FOR PRIMARY HEPATIC MALIGNANCY. Clinics in Liver Disease 2000;4:591-605. [DOI: 10.1016/s1089-3261(05)70128-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer. 2003;98:2664-2670. [PMID: 14669287 DOI: 10.1002/cncr.11869] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
253 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
254 Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661-669. [PMID: 16228211 DOI: 10.1007/s00330-005-0029-9] [Cited by in Crossref: 155] [Cited by in F6Publishing: 154] [Article Influence: 9.1] [Reference Citation Analysis]
255 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
256 Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) 2015;17:52-65. [PMID: 24961288 DOI: 10.1111/hpb.12273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
257 Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015; 7(16): 2009-2019 [PMID: 26261690 DOI: 10.4254/wjh.v7.i16.2009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
258 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
259 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. [Developments and perspectives in radioablative techniques]. Radiologe. 2007;47:1083-1088. [PMID: 17943265 DOI: 10.1007/s00117-007-1572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
260 Dudeck O, Ricke J. Advances in regional chemotherapy of the liver. Expert Opin Drug Deliv. 2011;8:1057-1069. [PMID: 21506902 DOI: 10.1517/17425247.2011.574125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
261 Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol. 2006;32:201-207. [PMID: 16373084 DOI: 10.1016/j.ejso.2005.11.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
262 Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. J Gastrointest Oncol. 2018;9:741-749. [PMID: 30151271 DOI: 10.21037/jgo.2018.05.13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
263 Li J, Huang S, Zhou Z, Lin W, Chen S, Chen M, Ye Y. Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma. Cancer Manag Res 2018;10:4945-57. [PMID: 30464595 DOI: 10.2147/CMAR.S178326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
264 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 30.9] [Reference Citation Analysis]
265 Livraghi T. Guidelines for treatment of liver cancer. European Journal of Ultrasound 2001;13:167-76. [DOI: 10.1016/s0929-8266(01)00129-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
266 Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006; 12(47): 7561-7567 [PMID: 17171782 DOI: 10.3748/wjg.v12.i47.7561] [Cited by in CrossRef: 185] [Cited by in F6Publishing: 185] [Article Influence: 11.6] [Reference Citation Analysis]
267 Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008;44:528-538. [PMID: 18242076 DOI: 10.1016/j.ejca.2008.01.004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 4.3] [Reference Citation Analysis]
268 Teratani T, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, Obi S, Sato S, Hamamura K, Omata M. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer. 2002;95:816-823. [PMID: 12209726 DOI: 10.1002/cncr.10735] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
269 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
270 Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann R, Jakobs T, Helmberger T. Update Chemoperfusion und -embolisation. Radiologe 2007;47:1097-108. [DOI: 10.1007/s00117-007-1587-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
271 Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15 Suppl 4:42-52. [PMID: 21115580 DOI: 10.1634/theoncologist.2010-s4-42] [Cited by in Crossref: 102] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
272 Franklin JM, Gebski V, Poston GJ, Sharma RA. Clinical trials of interventional oncology—moving from efficacy to outcomes. Nat Rev Clin Oncol 2015;12:93-104. [DOI: 10.1038/nrclinonc.2014.199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
273 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
274 Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119-126. [PMID: 11012432 DOI: 10.1148/radiology.217.1.r00se02119] [Cited by in Crossref: 365] [Cited by in F6Publishing: 325] [Article Influence: 16.6] [Reference Citation Analysis]
275 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
276 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
277 Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10:425-434. [PMID: 19721826 DOI: 10.3348/kjr.2009.10.5.425] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 7.4] [Reference Citation Analysis]
278 Zhu H, Zhou K, Zhang L, Jin C, Peng S, Yang W, Li K, Su H, Chen W, Bai J, Wu F, Wang Z. High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: Role of partial rib resection. European Journal of Radiology 2009;72:160-6. [DOI: 10.1016/j.ejrad.2008.07.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
279 Bruix J, Bru C. Rationale for Non-surgical Interventional Treatment of Hepatocellular Carcinoma. In: Bartolozzi C, Lencioni R, editors. Liver Malignancies. Berlin: Springer Berlin Heidelberg; 1999. pp. 245-53. [DOI: 10.1007/978-3-642-58641-5_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
280 Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
281 Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, Onozawa S, Kumita SI. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(37): 13453-13465 [PMID: 25309076 DOI: 10.3748/wjg.v20.i37.13453] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
282 Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:427-37. [DOI: 10.1097/01.cad.0000127330.21686.26] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
283 Gunvén P. Liver embolizations in oncology: A review: Part I. Arterial (chemo)embolizations. Med Oncol 2008;25:1-11. [DOI: 10.1007/s12032-007-0039-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
284 Song BC, Suh DJ, Yang SH, Lee HC, Chung YH, Sung KB, Lee YS. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J Clin Gastroenterol. 2002;35:398-402. [PMID: 12394228 DOI: 10.1097/00004836-200211000-00008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
285 J. Cheng S, Pratt DS, Freeman RB, Kaplan MM, Wong JB. LIVING-DONOR VERSUS CADAVERIC LIVER TRANSPLANTATION FOR NON-RESECTABLE SMALL HEPATOCELLULAR CARCINOMA AND COMPENSATED CIRRHOSIS: A DECISION ANALYSIS1: . Transplantation 2001;72:861-8. [DOI: 10.1097/00007890-200109150-00021] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 4.0] [Reference Citation Analysis]
286 Yan FH, Zhou KR, Cheng JM, Wang JH, Yan ZP, Da RR, Fan J, Ji Y. Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE. World J Gastroenterol 2002; 8(4): 658-662 [PMID: 12174374 DOI: 10.3748/wjg.v8.i4.658] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
287 Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Cascinu S, Scartozzi M. Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int 2016;2016:7196280. [PMID: 27314036 DOI: 10.1155/2016/7196280] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
288 Fisher RA, Maroney TP, Fulcher AS, Maluf D, Clay JA, Wolfe LG, Dawson S 3rd, Cotterell A, Stravitz RT, Luketic VA, Shiffman M, Sterling RK, Posner MP. Hepatocellular carcinoma: strategy for optimizing surgical resection, transplantation and palliation. Clin Transplant 2002;16 Suppl 7:52-8. [PMID: 12372045 DOI: 10.1034/j.1399-0012.16.s7.8.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
289 Zhao B, Lu J, Yin J, Liu H, Guo X, Yang Y, Ge N, Zhu Y, Zhang H, Xing J. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int. 2012;32:1451-1459. [PMID: 22809120 DOI: 10.1111/j.1478-3231.2012.02849.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
290 Ramsey DE, Geschwind JH. Chemoembolization of hepatocellular carcinoma—what to tell the skeptics: Review and meta-analysis. Techniques in Vascular and Interventional Radiology 2002;5:122-6. [DOI: 10.1053/tvir.2002.36418] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
291 Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol. 2003;26:344-349. [PMID: 12902882 DOI: 10.1097/01.coc.0000020588.20717.bb] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
292 Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190:608-615. [PMID: 18287429 DOI: 10.2214/ajr.07.2879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
293 Lee KT, Lu YW, Wang SN, Chen HY, Chuang SC, Chang WT, Shi HY, Ker CG, Chiu HC. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009;99:343-50. [PMID: 19226530 DOI: 10.1002/jso.21248] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
294 Jang JW, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, Kim CW, Chang UI, Nam SW, Cha SB. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol. 2007;59:9-15. [PMID: 16614848 DOI: 10.1007/s00280-006-0239-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
295 López-benítez R, Radeleff B, Barragán-campos H, Noeldge G, Grenacher L, Richter G, Sauer P, Büchler M, Kauffmann G, Hallscheidt P. Acute Pancreatitis after Embolization of Liver Tumors: Frequency and Associated Risk Factors. Pancreatology 2007;7:53-62. [DOI: 10.1159/000101878] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
296 Osada S, Imai H, Tomita H, Tokuyma Y, Okumura N, Sakashita F, Nonoka K, Sugiyama Y. Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J Gastroenterol Hepatol 2006;21:988-93. [DOI: 10.1111/j.1440-1746.2006.04223.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
297 Aguayo A, Patt YZ. Nonsurgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2001;5:175-89. [DOI: 10.1016/s1089-3261(05)70160-4] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
298 Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008;8:351. [PMID: 19038025 DOI: 10.1186/1471-2407-8-351] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 7.1] [Reference Citation Analysis]
299 Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M, Sasaki Y. Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 2010;45:60-7. [DOI: 10.1007/s00535-009-0109-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
300 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:401-20. [DOI: 10.1016/j.cld.2015.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
301 Coriat R, Mir O, Cessot A, Brezault C, Ropert S, Durand JP, Cacheux W, Chaussade S, Goldwasser F. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs. 2012;30:376-381. [PMID: 20798975 DOI: 10.1007/s10637-010-9525-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
302 Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z. Effect of Transcatheter Hepatic Arterial Embolization on Angiogenesis in an Animal Model. Investigative Radiology 2006;41:516-21. [DOI: 10.1097/01.rli.0000209663.00629.8a] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
303 Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006;9:125-132. [PMID: 17561215 DOI: 10.1053/j.tvir.2007.02.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
304 Oliveri RS, Wetterslev J, Gluud C; Cochrane Hepato-Biliary Group. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd004787.pub2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
305 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1294] [Article Influence: 161.9] [Reference Citation Analysis]
306 Wang J, Mao Y, Liu Y, Chen Z, Chen M, Lao X, Li S. Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment. J Gastrointest Surg. 2017;21:1128-1135. [PMID: 28397025 DOI: 10.1007/s11605-017-3420-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
307 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
308 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
309 Ray CE Jr, Haskal ZJ, Geschwind JF, Funaki BS. The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. J Vasc Interv Radiol 2011;22:1693-6. [PMID: 22035882 DOI: 10.1016/j.jvir.2011.09.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
310 Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012;23:317-22.e1. [PMID: 22265248 DOI: 10.1016/j.jvir.2011.11.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
311 Huang YH, Chen CH, Chang TT, Chen SC, Chiang JH, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, Huo TI, Lee SD, Wu JC. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. Aliment Pharmacol Ther 2005;21:687-94. [PMID: 15771754 DOI: 10.1111/j.1365-2036.2005.02404.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
312 Farinati F, Rinaldi M, Gianni S, Marin G. Transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatology 1998;28:1441-3. [DOI: 10.1002/hep.510280542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
313 Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther. 2010;10:507-519. [PMID: 20397916 DOI: 10.1586/era.10.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
314 Assumpcao L, Choti M, Pawlik TM, Gecshwind J, Kamel IR. Functional MR imaging as a new paradigm for image guidance. Abdom Imaging 2009;34:675-85. [DOI: 10.1007/s00261-008-9481-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
315 Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Baker T, Kulik L, Gupta R, Abecassis M, Benson AB, Omary R, Millender L, Kennedy A, Salem R. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. International Journal of Radiation Oncology*Biology*Physics 2011;79:163-71. [DOI: 10.1016/j.ijrobp.2009.10.062] [Cited by in Crossref: 131] [Cited by in F6Publishing: 109] [Article Influence: 11.9] [Reference Citation Analysis]
316 Yoon KT, Choi JW, Park JY, Ahn SH, Paik YH, Lee KS, Han KH, Chon CY, Kim DY. Clinical outcomes of systemic chemotherapy in hepatocellular carcinoma patients with multiple lung metastases. Korean J Hepatol 2008;14:360. [DOI: 10.3350/kjhep.2008.14.3.360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
317 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 21.1] [Reference Citation Analysis]
318 Ghidini M, Braconi C. Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne). 2015;2:36. [PMID: 26131450 DOI: 10.3389/fmed.2015.00036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
319 Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? Dig Liver Dis. 2010;42 Suppl 3:S258-S263. [PMID: 20547312 DOI: 10.1016/s1590-8658(10)60514-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
320 Fuchs K, Bize PE, Denys A, Borchard G, Jordan O. Sunitinib-eluting beads for chemoembolization: Methods for in vitro evaluation of drug release. International Journal of Pharmaceutics 2015;482:68-74. [DOI: 10.1016/j.ijpharm.2014.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
321 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
322 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
323 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]
324 Murthy R. New Horizons in Oncologic Embolotherapy. Journal of Vascular and Interventional Radiology 2002;13:P116-23. [DOI: 10.1016/s1051-0443(02)70074-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
325 Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. [PMID: 29621988 DOI: 10.1186/s12885-018-4308-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
326 Jhaveri K, Cleary S, Audet P, Balaa F, Bhayana D, Burak K, Chang S, Dixon E, Haider M, Molinari M, Reinhold C, Sherman M. Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). American Journal of Roentgenology 2015;204:498-509. [DOI: 10.2214/ajr.13.12399] [Cited by in Crossref: 57] [Cited by in F6Publishing: 19] [Article Influence: 8.1] [Reference Citation Analysis]
327 Wong N, Haydon A, Kemp W, Wijeratne P, Roberts S. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. Intern Med J 2013;43:197-203. [PMID: 22372378 DOI: 10.1111/j.1445-5994.2012.02755.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
328 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
329 Cha C, DeMatteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35:S130-S137. [PMID: 12449982 DOI: 10.1097/00004836-200211002-00009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
330 Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2010;126:2164-2174. [PMID: 19739081 DOI: 10.1002/ijc.24882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
331 Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D. Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2010;33:541-51. [DOI: 10.1007/s00270-009-9750-0] [Cited by in Crossref: 239] [Cited by in F6Publishing: 218] [Article Influence: 18.4] [Reference Citation Analysis]
332 Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Sun X. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer. 2007;121:416-424. [PMID: 17330237 DOI: 10.1002/ijc.22655] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
333 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
334 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-349] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
335 Miura JT, Gamblin TC. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Surg Oncol Clin N Am 2015;24:149-66. [PMID: 25444473 DOI: 10.1016/j.soc.2014.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
336 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
337 Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2009;20:S317-S323. [PMID: 19560017 DOI: 10.1016/j.jvir.2009.04.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
338 Dong S, Ye X, Yuan Z, Xu L, Xiao X. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization. European Journal of Radiology 2012;81:472-7. [DOI: 10.1016/j.ejrad.2010.12.081] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
339 Befeler A, Di Bisceglie AM. Treatment of hepatocellular carcinoma. Viruses and Liver Cancer. Elsevier; 2002. pp. 161-72. [DOI: 10.1016/s0168-7069(02)06074-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557-563. [PMID: 12783395 DOI: 10.1053/jlts.2003.50106] [Cited by in Crossref: 328] [Cited by in F6Publishing: 299] [Article Influence: 17.3] [Reference Citation Analysis]
341 Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst 2013;25:143-50. [PMID: 23932751 DOI: 10.1016/j.jnci.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
342 Scartozzi M, Faloppi L, Bianconi M, Giampieri R, Maccaroni E, Bittoni A, Del Prete M, Loretelli C, Belvederesi L, Svegliati Baroni G. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One. 2012;7:e32653. [PMID: 22461886 DOI: 10.1371/journal.pone.0032653] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
343 Salem R, Thurston KG. Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. Journal of Vascular and Interventional Radiology 2006;17:1425-39. [DOI: 10.1097/01.rvi.0000235779.88652.53] [Cited by in Crossref: 151] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
344 Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis. 2001;5:161-173. [PMID: 11218913 DOI: 10.1016/s1089-3261(05)70159-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
345 White JA, Gray SH, Li P, Simpson HN, McGuire BM, Eckhoff DE, Abdel Aal AMK, Saddekni S, Dubay DA. Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement? Hepatol Commun 2017;1:338-46. [PMID: 29404463 DOI: 10.1002/hep4.1046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
346 Lencioni R. Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 2012;1:41-50. [PMID: 24159570 DOI: 10.1159/000339019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
347 Shirai S, Sato M, Suwa K, Kishi K, Shimono C, Sonomura T, Kawai N, Tanihata H, Minamiguchi H, Nakai M. Feasibility and efficacy of single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma 8 cm or more with portal vein tumor thrombus in combination with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys. 2010;76:1037-1044. [PMID: 19540053 DOI: 10.1016/j.ijrobp.2009.03.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
348 Wong LL. Current status of liver transplantation for hepatocellular cancer. Am J Surg. 2002;183:309-316. [PMID: 11943133 DOI: 10.1016/s0002-9610(02)00785-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
349 Guo J, Wang W, Zhang Y, Xu L, Kong J. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis. J Gastrointest Oncol 2021;12:1838-50. [PMID: 34532132 DOI: 10.21037/jgo-21-370] [Reference Citation Analysis]
350 Liao GS, Yu CY, Shih ML, Chan DC, Liu YC, Yu JC, Chen TW, Hsieh CB. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2008;34:61-66. [PMID: 17434711 DOI: 10.1016/j.ejso.2007.02.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
351 Kokudo N, Makuuchi M. Current role of portal vein embolization/hepatic artery chemoembolization. Surg Clin North Am. 2004;84:643-657. [PMID: 15062666 DOI: 10.1016/j.suc.2003.12.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
352 Guo WJ, Li J, Ling WL, Bai YR, Zhang WZ, Cheng YF, Gu WH, Zhuang JY. Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats. World J Gastroenterol 2002; 8(3): 476-479 [PMID: 12046073 DOI: 10.3748/wjg.v8.i3.476] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
353 Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Rev Anticancer Ther 2013;13:1157-67. [PMID: 24099626 DOI: 10.1586/14737140.2013.845528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
354 Mahnken AH. [Transarterial ablative therapy of hepatocellular carcinoma]. Radiologe 2014;54:685-93. [PMID: 25047524 DOI: 10.1007/s00117-014-2655-1] [Reference Citation Analysis]
355 Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, Gallardo E, Kelekis A, Gouliamos A, Kelekis D. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2008;33:512-519. [PMID: 17938995 DOI: 10.1007/s00261-007-9334-x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
356 Turner PM, Turner TJ. Validation of the crisis triage rating scale for psychiatric emergencies. Can J Psychiatry. 1991;36:651-654. [PMID: 1773400 DOI: 10.1136/gut.51.4.459] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 2.5] [Reference Citation Analysis]
357 Kawaoka T, Aikata H, Takaki S, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Kamada K, Kitamoto M. Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. Hepatol Res. 2010;40:1082-1091. [PMID: 20880059 DOI: 10.1111/j.1872-034x.2010.00714.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
358 Tang S, Zhou H, Wu Q, Fu C, Tan L, Ren X, Huang Z, Chen X, Ren J, Meng X. Porous PLGA microspheres with recruited ions and doxorubicin for triple-combination therapy of larger hepatocellular carcinoma. J Mater Chem B 2017;5:9025-32. [PMID: 32264130 DOI: 10.1039/c7tb01472d] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
359 Grasso A, Watkinson AF, Tibballs JM, Burroughs AK. Radiofrequency ablation in the treatment of hepatocellular carcinoma--a clinical viewpoint. J Hepatol. 2000;33:667-672. [PMID: 11059876 DOI: 10.1016/s0168-8278(00)80023-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
360 Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged?: Validation of a new prognostic system. Cancer 2000;89:2266-73. [DOI: 10.1002/1097-0142(20001201)89:11<2266::aid-cncr15>3.0.co;2-0] [Cited by in Crossref: 99] [Article Influence: 4.5] [Reference Citation Analysis]